YMRC
AVDL

Yorktown Management & Research Company’s Avadel Pharmaceuticals AVDL Stock Holding History

Yorktown Management & Research Company’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-25,000
Closed -$260K – 344
2016
Q4 		$260K Hold
25,000
– – 0.07% 219
2016
Q3 		$310K Hold
25,000
– – 0.07% 151
2016
Q2 		$269K Buy
+25,000
New +$267K 0.06% 204

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Yorktown Management & Research Company's AVDL Position: Q1 2017 in Review

Yorktown Management & Research Company sold out of Avadel Pharmaceuticals (AVDL) in Q1 2017, closing a stake of 25,000 shares — an estimated $260K sold.

Yorktown Management & Research Company first reported a position in AVDL in Q2 2016 and held it in 3 quarters. The position peaked at $310K in Q3 2016. 74 funds tracked by Wall St. Rank hold AVDL as of Q1 2017.

  • Yorktown Management & Research Company reported no remaining Avadel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Yorktown Management & Research Company sold 25,000 Avadel Pharmaceuticals shares in Q1 2017, an estimated $260K.
  • Yorktown Management & Research Company first reported a position in Avadel Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Yorktown Management & Research Company's Avadel Pharmaceuticals position peaked at $310K in Q3 2016.
  • 74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2017.

Based on Yorktown Management & Research Company's 13F filing for Q1 2017, filed 4 May 2017.